Skip to main content
Imunon, Inc. logo

Imunon, Inc. — Investor Relations & Filings

Ticker · IMNN ISIN · US15117N6022 US Manufacturing
Filings indexed 1,030 across all filing types
Latest filing 2026-05-12 Interim / Quarterly Rep…
Country US United States of America
Listing US IMNN

About Imunon, Inc.

https://imunon.com/

Imunon, Inc. is a clinical-stage biotechnology company that develops novel immunotherapies and DNA-based vaccines. The company's core focus is on creating treatments for challenging conditions, including cancer and infectious diseases, by harnessing the patient's immune system. Its proprietary technology platforms are centered on immunology and nucleic acid-based therapies. The lead candidate in its pipeline is IMNN-001, a DNA-based immunotherapy in clinical development for advanced ovarian cancer. Imunon oversees the complete drug development lifecycle, from initial research and discovery to manufacturing in its in-house GMP-compliant facility.

Recent filings

Filing Released Lang Actions
10-Q - Imunon, Inc. (0000749647) (Filer)
Interim / Quarterly Report
2026-05-12 English
8-K - Imunon, Inc. (0000749647) (Filer)
Regulatory Filings
2026-05-12 English
ARS
Annual Report
2026-05-04 English
8-K - Imunon, Inc. (0000749647) (Filer)
Regulatory Filings
2026-05-04 English
DEF 14A - Imunon, Inc. (0000749647) (Filer)
Proxy Solicitation & Information Statement
2026-05-04 English
10-K - Imunon, Inc. (0000749647) (Filer)
Annual Report FY 2025
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.